Teladoc Health (TDOC) Expected to Announce Earnings on Wednesday

Teladoc Health (NYSE:TDOC) will likely be releasing its earnings data after the market closes on Wednesday, February 26th. Analysts expect Teladoc Health to post earnings of ($0.21) per share and revenue of $639.44 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Teladoc Health Stock Performance

NYSE:TDOC opened at $11.40 on Tuesday. The company has a market cap of $1.96 billion, a price-to-earnings ratio of -1.97 and a beta of 1.04. The company has a quick ratio of 1.69, a current ratio of 1.73 and a debt-to-equity ratio of 0.66. Teladoc Health has a 52 week low of $6.76 and a 52 week high of $15.95. The company has a fifty day simple moving average of $10.56 and a two-hundred day simple moving average of $9.50.

Insider Activity at Teladoc Health

In related news, insider Carlos Nueno sold 2,389 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $11.93, for a total value of $28,500.77. Following the transaction, the insider now owns 2,890 shares in the company, valued at $34,477.70. The trade was a 45.25 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.95% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on TDOC. Deutsche Bank Aktiengesellschaft upped their price target on Teladoc Health from $10.00 to $12.00 and gave the stock a “hold” rating in a report on Friday, November 1st. Bank of America upped their target price on shares of Teladoc Health from $11.50 to $13.50 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Royal Bank of Canada lifted their price target on shares of Teladoc Health from $11.00 to $12.00 and gave the stock an “outperform” rating in a research note on Friday, January 24th. Oppenheimer dropped their price objective on shares of Teladoc Health from $14.00 to $12.00 and set an “outperform” rating on the stock in a research report on Friday, January 24th. Finally, Barclays boosted their target price on shares of Teladoc Health from $10.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday, October 31st. Thirteen analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $11.81.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.